Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00610571 · ClinicalTrials.gov registry record · Phase 1
Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
A Phase 1 study of Glioblastoma and Gliosarcoma, sponsored by Katy Peters.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT00610571 is a Phase 1 study of Glioblastoma and Gliosarcoma that has completed, run by Katy Peters. The registered enrollment target is 62 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00610571, a Phase 1 study of Glioblastoma and Gliosarcoma, has completed, sponsored by Katy Peters.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
Objectives: * To determine the maximum tolerated dose of oral topotecan when administered with Temodar to patients with malignant glioma * To characterize any toxicity associated with the combination oral topotecan and Temodar. * To observe patients for clinical antitumor response when treated with oral topotecan and Temodar.
Conditions Studied
Interventions
- DRUG Oral Topotecan and Temodar
Study Locations (1)
North Carolina
- Duke University Health System - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2004-04 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00610571
The ClinicalTrials.gov registry entry for NCT00610571 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (43% lower). The listed sponsor is Katy Peters, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Oral Topotecan and Temodar is the first listed.
NCT00610571 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00610571 about?
NCT00610571 is a clinical study titled "Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas". Objectives: * To determine the maximum tolerated dose of oral topotecan when administered with Temodar to patients with malignant glioma * To characterize any toxicity associated with the combination oral topotecan and Temodar. * To observe patients for clinical antitumor response when treated with...
What is the current status of trial NCT00610571?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2004-04. Estimated completion is 2012-04.
What conditions does trial NCT00610571 study?
This clinical trial studies the following conditions: Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma.
What interventions are being tested in trial NCT00610571?
The interventions under investigation include: Oral Topotecan and Temodar (DRUG).
Who is sponsoring clinical trial NCT00610571?
This trial is sponsored by Katy Peters, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00610571 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.